Cheng, Hsin-Lin
Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways. [electronic resource]
- Oncotarget Mar 2016
- 9742-58 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
ISSN: 1949-2553
Standard No.: 10.18632/oncotarget.7138 doi
Subjects--Topical Terms: Biological Transport--drug effects Bone Density Conservation Agents--pharmacology Bone Neoplasms--drug therapy Cadherins--metabolism Cell Line, Tumor Cell Movement--drug effects Cell Survival--drug effects Diphosphonates--pharmacology Diterpenes--pharmacology Epithelial-Mesenchymal Transition--drug effects Farnesol--pharmacology Focal Adhesion Kinase 1--metabolism Focal Adhesion Protein-Tyrosine Kinases--metabolism Humans Imidazoles--pharmacology JNK Mitogen-Activated Protein Kinases--metabolism MAP Kinase Signaling System--drug effects Neoplasm Invasiveness--pathology Nuclear Proteins--metabolism Osteoporosis--chemically induced Osteosarcoma--drug therapy Phosphorylation--drug effects Prenylation--drug effects Proto-Oncogene Proteins pp60(c-src)--metabolism Snail Family Transcription Factors--metabolism Twist-Related Protein 1--metabolism Zoledronic Acid cdc42 GTP-Binding Protein--metabolism p38 Mitogen-Activated Protein Kinases--metabolism rho-Associated Kinases--metabolism